Oslo, Norway 26 February 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, today announces that CEO Dr. Erik Digman Wiklund and CSO Dr. Victor Levitsky have been invited to present the circVec platform and benefits of circular RNA at two upcoming biopharma industry conferences in Basel, Switzerland, and Stockholm, Sweden.
The presentations will detail the advantages and potential of circular RNA to improve on current mRNA-based technology for a range of therapeutic applications. Circio’s latest circVec 3.0 generation demonstrates significantly increased and prolonged protein expression, with up to 75 times half-life extension for circRNA compared to conventional linear mRNA in mouse models.
RNA Leaders Europe Congress
Title: Deploying circular RNA expression to boost gene therapy – AAV and beyond
Time & place: 5 March 2025, 11:05 CET, Basel, Switzerland
Presenter: Dr. Erik Digman Wiklund, CEO
Biologics World Nordics 2025
Title: CircVec – A Novel Payload Expression Platform Based on Circular RNA Biogenesis: Features and Opportunities
Time & place: 5 March 2025, 11:35 CET, Stockholm, Sweden
Presenter: Dr. Victor Levitsky, CSO
These invitations to present at important RNA industry conferences highlight Circio´s position as a leader in circRNA placed along other pioneering RNA companies such as Alnylam, CureVac and Sail Biomedicines. It follows the recent invitation by Nature Review Genetics to author a comprehensive review article on the therapeutic potential of synthetic circular RNA and vector-based circular RNA expression.
The presentations will be made available on Circio´s webpage on the respective dates.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Neil Hunter – Hunter PR
Phone:+44 7821 255568
Email: neiljameshunter@gmail.com
About Circio
Building next generation RNA technology for nucleic acid medicine
Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression platform for novel DNA, RNA and viral therapeutics. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells, which can be deployed in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. The circVec platform has demonstrated up to 15-fold enhanced and more significantly more durable protein expression vs. classic mRNA vector systems and has the potential to become a new gold-standard platform technology for nucleic acid and viral therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in two clinical trials: RAS-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway. These studies are being run through academic and industry collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.